DrugBiological
Tositumomab clinical trials
Includes 23 studies of Tositumomab I-131.
- studies test it
- 27
- open now
- 0
- in phase 3
- 1
- first study started
- 1995
How studies write it
Studies that test it under each name
Name
Combined with it in one product
Studies by the year they started
25 studies that test it; most in 2007 (6)
| Year | Studies |
|---|---|
| 1995 | 1 |
| 1996 | 2 |
| 1998 | 4 |
| 1999 | 3 |
| 2000 | 2 |
| 2003 | 1 |
| 2004 | 3 |
| 2005 | 2 |
| 2007 | 6 |
| 2009 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 19
- Phase 3
- 1
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 17 · Other 10
GlaxoSmithKline (11) · Corixa Corporation (6) · University of Michigan Rogel Cancer Center (1) · SWOG Cancer Research Network (1) · Weill Medical College of Cornell University (1) · Fred Hutchinson Cancer Center (1) · Duke University (1) · Susan Knox (1)
Often tested with
Tested in the same studies.
Rituximab (2) · Cyclophosphamide (2) · Doxorubicin (2) · Bortezomib (2) · Prednisone (1) · Vincristine (1) · Etoposide (1) · Cytarabine (1)
Studies
Open first, then newest update. How each study uses tositumomab is read from its arms, and is right about nine times in ten.
Testing it · 27
- Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple MyelomaCompletedPhase 2University of Michigan Rogel Cancer CenterNCT00135200Written as Iodine I 131 Tositumomab
- A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's LymphomaTerminatedPhase 2Rush University Medical CenterNCT00479167Written as Bortezomib and Tositumomab I-131
- S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin LymphomaCompletedPhase 2SWOG Cancer Research NetworkNCT00770224Written as tositumomab
- Phase 1 Study of Radiosensitization Using Bortezomib in Relapsed Non-Hodgkin's Lymphoma Patients Receiving RadioimmunotherapyCompletedPhase 1Weill Medical College of Cornell UniversityNCT00777114Written as bortezomib, tositumomab
- Tositumomab and Iodine I 131 Tositumomab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First RemissionCompletedPhase 2Fred Hutchinson Cancer CenterNCT00476047Written as Tositumomab and Iodine I 131 Tositumomab
- Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Non Hodgkin's Lymphoma (NHL) Patients With Greater Than 25% Bone Marrow InvolvementCompletedPhase 1GlaxoSmithKlineNCT00992758Written as Iodine-131 Anti-B1 Antibody
- Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins LymphomaCompletedPhase 2Duke UniversityNCT00577629Written as tositumomab
- Phase 2 Study of Bexxar in Relapsed/Refractory DLCLCompletedPhase 2Susan KnoxNCT00490009Written as Bexxar
- Study of Bexxar <Tositumomab> Combined With External Beam Radiation TherapyTerminatedPhase 2Stanford UniversityNCT00490490Written as Bexxar (tositumomab)
- Study of Safety and Efficacy of a Sequential Regimen Consisting of Three Cycles of Fludarabine Followed by Tositumomab and Iodine I 131 TositumomabCompletedPhase 2GlaxoSmithKlineNCT00933335Written as Tositumomab and Iodine I 131 Tositumomab
- Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive HistologyCompletedPhase 2GlaxoSmithKlineNCT00950755Written as tositumomab and Iodine I 131 tositumomab (anti-B1 antibody)
- Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab) for Previously Untreated, Advanced-stage, Low Grade Non-Hodgkin's LymphomaCompletedPhase 2GlaxoSmithKlineNCT00996996Written as Tositumomab and Iodine I 131 Tositumomab (Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody)
- Iodine-131 Anti-B1 Antibody Consolidation for Patients With Non-Hodgkin's Lymphoma Following First-line CHOPCompletedPhase 2GlaxoSmithKlineNCT01868035Written as tositumomab and iodine I-131 tositumomab
- Retreatment of Patients With Non-Hodgkin's Lymphoma Who Have Previously Responded to Iodine-131 Anti B1 AntibodyCompletedPhase 2GlaxoSmithKlineNCT00938041Written as Tositumomab and Iodine I 131 Tositumomab
- Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins LymphomaCompletedPhase 3GlaxoSmithKlineNCT00268983Written as Tositumomab and Iodine I 131 Tositumomab
- Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-refractory Low-grade or Transformed Low-grade B-cell Non-Hodgkin's LymphomaCompletedPhase 2GlaxoSmithKlineNCT00989664Written as Tositumomab and Iodine I 131 Tositumomab
- Dosimetry/Validation Study of 131Iodine-Anti B1 (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas That Have Transformed to Higher Grade HistologiesCompletedPhase 2GlaxoSmithKlineNCT01224821Written as Tositumomab (Anti-B1 Antibody) and Iodine-131 Tositumomab
- Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous TransplantCompletedPhase 1University of PennsylvaniaNCT00434629Written as Bexxar
- Tositumomab And Iodine I 131-Tositumomab In Patients With Relapsed Indolent Non-Hodgkin's LymphomaCompletedPhase 2GlaxoSmithKlineNCT00240565Written as Tositumomab 450 mg
- Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and BexxarTerminatedPhase 2University of FloridaNCT00475332Written as Iodine I -01 Tositumomab (Bexxar)
See all 27 studies that test tositumomab →
Given in every arm · 1 — tositumomab is usual care beside what is tested
Codes
What other systems call tositumomab · ClinicalTrials.gg INT014147
- UNII (FDA) 0343IGH41UTOSITUMOMABConfirmed FDA, Wikidata
- RxNorm 263010Confirmed FDA, Wikidata
- Wikidata Q3995913tositumomabConfirmed FDA, Wikidata
- NCI Thesaurus C2543TositumomabOne source FDA
- DrugBank DB00081One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 0343IGH41U | TOSITUMOMAB | Confirmed FDA, Wikidata |
| RxNorm | 263010 | — | Confirmed FDA, Wikidata |
| Wikidata | Q3995913 | tositumomab | Confirmed FDA, Wikidata |
| NCI Thesaurus | C2543 | Tositumomab | One source FDA |
| DrugBank | DB00081 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.